Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Pharmaceutical Sales by Quarter
Pharmaceutical Sales — United States share of Pharmaceutical revenue (%) (%)
Merck Pharmaceutical Sales: 59.8% in Q2 2026, up 0.5 pts from a year earlier.
Latest, Q2 2026
59.8%
Period ended Jun 30, 2026
Change on a year earlier
+0.5 pts
59.3% in Q2 2025
History
40 quarters
Since Q1 2016
Sources
16
Documents cited below
Where the Q2 2026 figure comes from
“United States | || % Pharmaceutical Sales | 59.3 | % | 59.8 | % | 59.6 | % | 58.1 | % | 59.3 | % | 58.7 | % | 60.8 | % | 58.4 | % | 59.2 | %”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Pharmaceutical Sales (%), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma-geo-us-share
See every metric in the Merck KPI table. Data updated Oct 26, 2026.